For decades, psilocybin — the compound found in so-called “magic mushrooms” — was dismissed, criminalized, and laughed out of serious medical conversations. In 2026, it may be on the verge of becoming a federally approved antidepressant.
On February 17, 2026, London-based biotech company Compass Pathways announced that its synthetic psilocybin drug, COMP360, hit the primary endpoint in its second Phase 3 clinical trial — the last major scientific hurdle before a formal FDA application. This comes on the heels of a successful first Phase 3 trial in 2025. Two wins. Back to back. Over 1,000 participants across both studies. The science is stacking up.
What the Trials Actually Showed
The second trial, called COMP006, enrolled 568 participants across North America and Europe — all diagnosed with treatment-resistant depression (TRD), meaning standard antidepressants had failed them. Patients received two doses of COMP360 25mg, administered three weeks apart.
The results were statistically significant with a p-value under 0.001 — the gold standard in clinical research. Depression severity scores dropped meaningfully, and nearly 39% of participants in the higher dose group showed a clinically meaningful reduction in symptoms. Perhaps most striking: the effect kicked in as early as the day after the first dose and held for at least 26 weeks — from just one or two administrations.
To be clear: that’s not a daily pill. That’s one or two doses showing effects lasting six months.
What Comes Next: The FDA Clock Is Now Running
Compass Pathways has already requested a meeting with the FDA to discuss a rolling New Drug Application (NDA) — a process that allows sections of the application to be submitted and reviewed as they’re completed, rather than all at once. The company is targeting a full NDA submission in Q4 2026, with longer-term 26-week data from COMP006 expected in Q3.
COMP360 already holds FDA Breakthrough Therapy designation for treatment-resistant depression — a status that signals the agency believes the drug may offer substantial improvement over current options. That designation typically fast-tracks the review process.
Wall Street is paying attention. Analysts at TD Cowen have stated they strongly believe COMP360 will receive approval. One Stifel analyst noted the results “clearly met the Street’s bar for success.” For reference, J&J’s Spravato — a ketamine-based treatment for TRD — pulled in $1.7 billion in sales last year after FDA approval in 2019. COMP360 would compete in that same space.
TEG Hot Take: This Is Bigger Than People Are Treating It
Let’s talk about what this actually means for real people.
Over 122 million Americans live in areas with mental health clinician shortages. Roughly one-third of people with major depression don’t respond to standard antidepressants. These are people cycling through medications for years, sometimes decades, with no relief. They’re not a niche population — they are your family members, your neighbors, your coworkers, your veterans.
And the current answer from mainstream medicine has largely been: try another pill. Maybe two. Maybe three.
COMP360 is proposing something fundamentally different: a guided, supervised, limited-dose treatment that potentially resets how the brain handles depression — not a lifetime prescription, but a reset. The science behind it involves neuroplasticity and serotonin receptor modulation, essentially giving the brain a window to rewire patterns that have been locked in place.
Is it perfect? No. Is it a magic cure? Absolutely not. Are there real questions still on the table — like who it works for, who it doesn’t, and what the long-term risks look like beyond 26 weeks? Yes. Peer-reviewed publication of the full datasets is still pending.
But two consecutive Phase 3 wins, with over a thousand participants, zero unexpected safety red flags, and effects lasting six months from one or two doses? That’s not a fluke. That’s a signal.
The Bigger Picture: Psychedelics Are Going Mainstream
COMP360 wouldn’t be the first psychedelic-adjacent treatment approved in the U.S. — that distinction belongs to J&J’s Spravato (esketamine), which cleared FDA in 2019. But psilocybin, a “classic psychedelic,” is a different category entirely. Its approval would mark a genuine cultural and medical turning point.
Multiple other psychedelic compounds — including MDMA-assisted therapy for PTSD — have also been working through clinical trials, though with more mixed results. The field as a whole is accelerating. Compass CMO Guy Goodwin stated plainly: “Psychedelic drugs are poised to integrate into mainstream psychiatry, challenging traditional pharmacotherapies that require long-term daily tablet taking.”
That’s not fringe science anymore. That’s a chief medical officer of a NASDAQ-listed biotech company telling the world the paradigm is shifting.
What to Watch
- Q3 2026: 26-week long-term data from COMP006 releases
- Q4 2026: Compass submits NDA to FDA
- 2027: Potential FDA decision window
- Watch: Whether the current administration’s FDA stance on psychedelics shifts the timeline in either direction
This story isn’t over. It’s just getting started. And TEG Report will be watching every move.
Sources: Compass Pathways press releases (Feb. 17, 2026), BioPharma Dive, Psychiatric Times, HCPLive, STAT News